Animals treated with in vivo FV vector gene therapy
| ID . | Weight at injection, kg . | Age at injection, d . | FV . | Dose of vector, IU . | Mobilization . | WBCs, × 109/L . | Estimated MOI* . |
|---|---|---|---|---|---|---|---|
| R2202 | NA | 1 | EF1α.GFP.2A.γC | 4.2 × 108 | No | NA | NA |
| R2203 | NA | 1 | EF1α.GFP.2A.γC | 4.2 × 108 | No | NA | NA |
| R2258 | 1.04 | 18 | EF1α.GFP.2A.γC | 4.0 × 108 | No | 7.67 | 1.21 |
| PGK.mCherry.2A.γC | 4.0 × 108 | ||||||
| R2260 | 1.05 | 18 | EF1α.mCherry.2A.γC | 4.0 × 108 | No | 6.64 | 1.40 |
| PGK.GFP.2A.γC | 4.0 × 108 | ||||||
| H864 | 0.8 | 16 | PGK.mCherry.2A.γC | 4.0 × 108 | G-CSF/ AMD3100 | 16.42 | 0.28 |
| H867 | 1.1 | 16 | PGK.mCherry.2A.γC | 4.0 × 108 | G-CSF/ AMD3100 | 18.04 | 0.26 |
| ID . | Weight at injection, kg . | Age at injection, d . | FV . | Dose of vector, IU . | Mobilization . | WBCs, × 109/L . | Estimated MOI* . |
|---|---|---|---|---|---|---|---|
| R2202 | NA | 1 | EF1α.GFP.2A.γC | 4.2 × 108 | No | NA | NA |
| R2203 | NA | 1 | EF1α.GFP.2A.γC | 4.2 × 108 | No | NA | NA |
| R2258 | 1.04 | 18 | EF1α.GFP.2A.γC | 4.0 × 108 | No | 7.67 | 1.21 |
| PGK.mCherry.2A.γC | 4.0 × 108 | ||||||
| R2260 | 1.05 | 18 | EF1α.mCherry.2A.γC | 4.0 × 108 | No | 6.64 | 1.40 |
| PGK.GFP.2A.γC | 4.0 × 108 | ||||||
| H864 | 0.8 | 16 | PGK.mCherry.2A.γC | 4.0 × 108 | G-CSF/ AMD3100 | 16.42 | 0.28 |
| H867 | 1.1 | 16 | PGK.mCherry.2A.γC | 4.0 × 108 | G-CSF/ AMD3100 | 18.04 | 0.26 |
IU, infectious units; MOI, multiplicity of infection; NA, not available; WBC, white blood cell.
MOI at the time of injection was calculated based on the number of virus particles injected divided by the estimated number of circulating WBCs (considering an average blood volume of 86 mL/kg).